Olic Ivna, Zivkovic Piero Marin, Zaja Ivan, Pavlovic Nikola, Kumric Marko, Bozic Josko
Department of Gastroenterology, University Hospital of Split, 21000 Split, Croatia.
Department of Internal Medicine, University of Split School of Medicine, 21000 Split, Croatia.
Pharmaceuticals (Basel). 2025 Sep 11;18(9):1359. doi: 10.3390/ph18091359.
Eosinophilic esophagitis (EoE) is a long-term, immune-driven condition of the esophagus, which can lead to severe fibrostenosis of the esophagus, and the aim is to control clinical, endoscopic, and histopathologic disorder activity. Currently, treatment options include the use of proton pump inhibitors, topical steroids, and dietary elimination as basic treatments; however, the introduction of dupilumab has provided an additional therapeutic approach. Numerous biologic agents target specific immune pathways, which are promising pharmacologic options in managing this progressive disease. The final goal is to treat the target, with complete resolution as the final objective. To accomplish this, however, effective agents capable of modifying the disease process are required. In this review, we aimed to provide an overall review of EoE therapeutics options, as well as the benefits and safety of new treatment strategies for EoE.
嗜酸性粒细胞性食管炎（EoE）是一种由免疫驱动的食管长期病症，可导致食管严重纤维狭窄，其目标是控制临床、内镜及组织病理学紊乱活动。目前，治疗选择包括使用质子泵抑制剂、局部类固醇和饮食排除作为基础治疗；然而，度普利尤单抗的引入提供了另一种治疗方法。众多生物制剂靶向特定免疫途径，在管理这种进展性疾病方面是有前景的药物选择。最终目标是治疗靶点，以完全缓解为最终目的。然而，要实现这一点，需要能够改变疾病进程的有效药物。在本综述中，我们旨在全面综述EoE的治疗选择，以及EoE新治疗策略的益处和安全性。
